The abstract is read at the publisher; the summary is JClub's.
MnCORM, a manganese(I) quinoline-based CO-releasing molecule, inhibited bladder cancer growth in an orthotopic nude mouse model after intravesical instillation at 1 mg kg−1.
- Why it matters: Systemic CO delivery is limited by haemoglobin binding and toxicity, so localized intravesical therapy is needed to translate CO’s anticancer potential for bladder cancer.
- What they did: The authors synthesized and characterized MnCORM, then tested anti-cancer effects in T24 and RT112 cells, 3D tumour spheroids, and a murine orthotopic bladder cancer model, using staining, TEM, and western blots.
- The result: MnCORM reduced viability and triggered AMPK activation, mitochondrial fission via Drp1, ROS accumulation, and mitophagy-associated cell death, with AMPK inhibition by Compound C mitigating cytotoxicity in T24 cells.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.